source
- Teva R&D chief Eric Hughes resigns, company taps innovative medicines head as interim leadTeva announced that its chief scientific officer for research and development, Eric Hughes, M.D., Ph.D., will leave the company. Hughes, who joined Teva in 2022 as executive vice president of globa…
- Evaxion Biotech Shifts R&D Focus Exclusively to Cancer Vaccines, Halts Infectious and Autoimmune ProgramsEvaxion Biotech announced it is ending its infectious disease and autoimmune research programs to concentrate solely on oncology. The company’s most advanced candidate is EVX-01, a therapeutic can…